000			02041 a2200613 4500
005			20250513231152.0
264		0	_c20010712
008			200107s 0 0 eng d
022			_a0301-0147
024	7		_a10.1159/000054193 _2doi
040			_aNLM _beng _cNLM
100	1		_aGaziano, J M
245	0	0	_aAspirin in the treatment and prevention of cardiovascular disease. _h[electronic resource]
260			_bHaemostasis _c2000
300			_a1-13 p. _bdigital
500			_aPublication Type: Comparative Study; Journal Article; Review
650	0	4	_aAcute Disease
650	0	4	_aAdult
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAspirin _xadverse effects
650	0	4	_aCardiovascular Diseases _xdrug therapy
650	0	4	_aCase-Control Studies
650	0	4	_aCohort Studies
650	0	4	_aCoronary Disease _xdrug therapy
650	0	4	_aCost-Benefit Analysis
650	0	4	_aCyclooxygenase Inhibitors _xpharmacology
650	0	4	_aDrug Costs
650	0	4	_aDrug Labeling
650	0	4	_aDrug Utilization
650	0	4	_aFemale
650	0	4	_aFibrinolytic Agents _xtherapeutic use
650	0	4	_aHemorrhage _xchemically induced
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMeta-Analysis as Topic
650	0	4	_aMiddle Aged
650	0	4	_aMyocardial Infarction _xdrug therapy
650	0	4	_aMyocardial Revascularization
650	0	4	_aPlatelet Aggregation Inhibitors _xadverse effects
650	0	4	_aPostoperative Complications _xprevention & control
650	0	4	_aPractice Guidelines as Topic
650	0	4	_aRandomized Controlled Trials as Topic
650	0	4	_aRecurrence
650	0	4	_aStreptokinase _xtherapeutic use
650	0	4	_aStroke _xprevention & control
650	0	4	_aThrombolytic Therapy
650	0	4	_aThrombosis _xprevention & control
650	0	4	_aTreatment Outcome
700	1		_aSkerrett, P J
700	1		_aBuring, J E
773	0		_tHaemostasis _gvol. 30 Suppl 3 _gp. 1-13
856	4	0	_uhttps://doi.org/10.1159/000054193 _zAvailable from publisher's website
999			_c11120842 _d11120842